Guest Column | June 2, 2016

ASCO To Take A Closer Look At Patient-Reported Outcomes In Clinical Trials And Cancer Care

By Joe O’Connell, MD, Vice President and Global Therapeutic Head for Hematology/ Oncology, INC Research/inVentiv Health Clinical Division

While the annual meetings of the American Society of Clinical Oncology (ASCO) can almost always be counted on to generate news about scientific breakthroughs in understanding and treating cancer, the theme for this year’s conference goes beyond that conventional approach. ASCO 2016 Annual Meeting will prominently feature discussions about how clinicians can best integrate recent advances, and particularly how to best assess the impact on real-world patients. This marks a pivotal time during which the cancer community is being challenged to think about drug benefit and risk – and of course, value – in some fundamentally different ways.

access the Guest Column!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Clinical Leader? Subscribe today.

Subscribe to Clinical Leader X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.

or

Subscribe to Clinical Leader

INC Research/inVentiv Health